This study tests a new medicine called **BAL0891** for people with very serious cancers. The study is in **Phase 1**, which is the first stage to see if the medicine is safe and how the body handles it. People with advanced solid tumors (cancers that spread) or a type of blood cancer called **relapsed or refractory acute myeloid leukemia (AML)** can join. The study will test BAL0891 alone or with other drugs, like **tislelizumab** or **paclitaxel**. The medicine is given through a needle into a vein (IV) on specific days and the amount will be increased gradually to find the safest dose. Scientists will look at how well the medicine works and any side effects.

• Participants will visit the clinic every 3 weeks for treatment.
• The study may last several months as doses are adjusted and monitored.
• There may be risks of side effects, as this is an early-stage trial.

People considering joining should understand they need to travel to the clinic regularly and may experience side effects as the medicine is tested for the first time in humans.